問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Dermatology

更新時間:2023-09-19

廖怡貞
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

4Cases

2025-03-01 - 2027-08-31

Phase II

Active
A single-therapy, multicenter, repeated-dose phase 2 trial was conducted to evaluate the safety of OBI-858 in subjects with moderate to severe frown lines.
  • Condition/Disease

    Moderate to severe frown lines

  • Test Drug

    OBI-858

Participate Sites
5Sites

Recruiting5Sites

2023-01-27 - 2025-09-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting2Sites

Terminated2Sites

2023-05-31 - 2027-08-21

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2027-05-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites